Compositions comprising peptide WKDEAGKPLVK
A composition comprising a cosmetically or pharmaceutically or therapeutically effective amount of a peptide comprising an amino acid sequence of SEQUENCE ID NO. 1. Modified peptides, and therapeutic and cosmetic uses of the peptide are also disclosed.
1. A composition comprising a peptide of up to 50 amino acids, the peptide comprising the amino acid sequence of SEQ ID NO: 1, or a variant thereof, the variant comprising no more than 3 amino acid alterations relative to SEQ ID NO: 1.
2. The composition of claim 1 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1, or a variant thereof, the variant comprising no more than 1 amino acid alteration relative to SEQ ID NO: 1.
3. The composition of claim 1 , in which the peptide is modified by modifications of side chains, incorporation of a protecting group, incorporation of up to 5 unnatural amino acids, cyclisation, conjugation to a conjugation partner, covalent binding to a binding partner, fusion to a fusion partner, PEGylation, amidation, acylation lipidation, or the incorporation of a cross-linker.
4. The composition of claim 1 , in which the peptide is modified with a modification group selected from polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran, pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide copolymer, polypropylene glycol, polyoxyethylated polyols, polyvinyl alcohol, colominic acids, carbohydrate based polymers, polymers of amino adds, or biotin derivatives; or that is modified with a N-terminal or C-terminal protecting group.
5. A pharmaceutical composition comprising a peptide of up to 50 amino acids, the peptide comprising the amino acid sequence of SEQ ID NO: 1, or a variant thereof, the variant comprising no more than 3 amino acid alterations relative to SEQ ID NO: 1, for use in a method of ameliorating diabetes or pre-diabetes, a method of lessening the symptoms of diabetes or pre-diabetes, a method of delaying the onset or progression of diabetes or pre-diabetes, and/or a method of reducing the incidence of diabetes or pre-diabetes in a treated population of diabetics or pre-diabetics.
6. The pharmaceutical composition of claim 5 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1, or a variant thereof, the variant comprising no more than 1 amino acid alteration relative to SEQ ID NO: 1.
7. The pharmaceutical composition of claim 5 , further comprising a suitable pharmaceutical carrier.
8. The pharmaceutical composition of claim 5 , wherein the diabetes is Type 2 diabetes.
9. The pharmaceutical composition of claim 5 , in which the composition is to be administered with one or more agents selected from the group consisting of: insulin; insulin analogues; insulin derivatives; glucagon-like peptide 1; glucagon-like peptide 2; derivatives glucagon-like like peptide 1; derivatives of glucagon-like peptide 2; analogues of glucagon-like peptide 1; and analogue of glucagon-like peptide 2.
10. The pharmaceutical composition of claim 5 , formulated for oral or parenteral administration to a patient.
11. The pharmaceutical composition of claim 5 , in which the peptide is modified by modifications of side chains, incorporation of a protecting group, incorporation of up to 5 unnatural amino acids, cyclisation, conjugation to a conjugation partner, covalent binding to a binding partner, fusion to a fusion partner, PEGylation, amidation, acylation lipidation, or the incorporation of a cross-linker.
12. The pharmaceutical composition of claim 5 , in which the peptide is modified with a modification group selected from polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide copolymer, polypropylene glycol, polyoxyethylated polyols, polyvinyl alcohol, colominic acids, carbohydrate based polymers, polymers of amino adds, or biotin derivatives; or is modified with a N-terminal or C-terminal protecting group.